Silexion Therapeutics Corp (NASDAQ:SLXN) Shares Shorted: Short Interest Down 96.7% in October

Silexion Therapeutics Corp (NASDAQ:SLXN) was the recipient of a large drop in short interest in the month of October. As of October 15th, there was short interest totaling 162,704 shares, a drop of 96.7% from the September 30th total of 4,925,958 shares. Approximately 2.9% of the shares of the stock are sold short. Based on an average daily volume of 1,598,172 shares, the short-interest ratio is currently 0.1 days.

Silexion Therapeutics Stock Performance

SLXN traded down $0.01 during trading on Monday, hitting $0.17. 1,207,104 shares of the company traded hands, compared to its average volume of 18,712,700. The stock’s 50-day simple moving average is $0.31 and its two-hundred day simple moving average is $7.45. Silexion Therapeutics has a 1 year low of $0.14 and a 1 year high of $35.60.

Silexion Therapeutics (NASDAQ:SLXN) last announced its quarterly earnings results on Saturday, August 15th. The company reported ($5.17) EPS for the quarter, topping the consensus estimate of ($21.20) by $16.03. As a group, sell-side analysts forecast that Silexion Therapeutics will post -4.70 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on SLXN shares. Weiss Ratings restated a “sell (e+)” rating on shares of Silexion Therapeutics in a research note on Friday, September 11th. Maxim Group downgraded shares of Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 29th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold”.

Silexion Therapeutics Company Profile

Silexion Therapeutics Ltd. (NASDAQ: SLXN) is a clinical-stage biotechnology company focused on developing targeted treatments for cancer, with an emphasis on tumors driven by mutations in the KRAS gene. The company’s primary focus is pancreatic cancer, a disease in which KRAS mutations are common and historically difficult to treat.

Silexion is developing RNA-based therapies designed to suppress cancer-promoting KRAS activity. Its pipeline has included siG12D-LODER, a locally administered therapy intended to deliver small interfering RNA against the KRAS G12D mutation, and SIL-204, a next-generation formulation designed to support broader or systemic delivery of KRAS-targeting treatment.

The company originated in Israel and has conducted its research and clinical development activities through Israeli and international collaborations and clinical programs.